Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Specimen Handling 40Magnetic Resonance Spectroscopy 28Carboplatin 19Gemcitabine 18Biopsy 17Cyclophosphamide 15fludarabine 14Paclitaxel 14Cisplatin 14pembrolizumab 13Oxaliplatin 12Dexamethasone 12Radiotherapy 11Injections 11Nivolumab 10Interviews as Topic 9venetoclax 8Irinotecan 8Fluorouracil 8Bevacizumab 8X-Rays 7Radiosurgery 7Drug Therapy 7Capecitabine 7Bortezomib 7cemiplimab 6Rituximab 6Pemetrexed 6Doxorubicin 6Calcium Dobesilate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Emapalumab × 30 days × Clear all
NCT07567014 2026-05-06

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

NYU Langone Health

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡